Jeffrey Asbury, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1528062551
Payments from drug & device makers
Across 563 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Amgen$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$968
- Novartis$727
- Boehringer Ingelheim$517
- AstraZeneca$477
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,314100%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 92 | $1,757 |
| Amgen | 74 | $1,017 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 71 | $968 |
| Novartis | 83 | $727 |
| Boehringer Ingelheim | 32 | $517 |
| AstraZeneca | 24 | $477 |
| Merck | 27 | $452 |
| Novo Nordisk | 29 | $443 |
| E.r. Squibb & Sons, L.L.C. | 30 | $364 |
| Pfizer | 31 | $250 |
| Kowa Pharmaceuticals America, Inc. | 11 | $177 |
| Esperion Therapeutics, Inc. | 10 | $170 |
| Bayer | 8 | $151 |
| Regeneron Healthcare Solutions, Inc. | 8 | $140 |
| Heartflow, Inc. | 1 | $119 |
| Lundbeck LLC | 6 | $105 |
| Medicure Pharma Inc. | 2 | $90 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Amarin Pharma, Inc. | 3 | $45 |
| Abiomed | 1 | $44 |
| Lilly USA, LLC | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 2 | $34 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Atricure, Inc. | 1 | $24 |
| Boston Scientific | 1 | $21 |
| Abbott | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $9 |
| Althera Pharmaceuticals LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$343
How this compares
$8,355 in reported general payments places this provider in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 791 | $755,848 |
| OzempicSemaglutide | 345 | $389,857 |
| Repatha SureclickEvolocumab | 398 | $331,330 |
| XareltoRivaroxaban | 346 | $329,292 |
| MounjaroTirzepatide | 224 | $264,717 |
| VascepaIcosapent Ethyl | 287 | $170,870 |
| JardianceEmpagliflozin | 146 | $141,925 |
| EntrestoSacubitril/Valsartan | 97 | $109,106 |
| FarxigaDapagliflozin Propanediol | 87 | $72,156 |
| Praluent PenAlirocumab | 61 | $54,102 |
| MultaqDronedarone Hcl | 30 | $38,025 |
| BrilintaTicagrelor | 29 | $24,933 |
| WegovySemaglutide | 16 | $22,748 |
| TrulicityDulaglutide | 18 | $22,742 |
| Icosapent Ethyl | 85 | $19,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $250 | $755,848791 claims |
| Novo NordiskOzempic, Wegovy | $443 | $412,605361 claims |
| Johnson & JohnsonXarelto | $1,757 | $329,292346 claims |
| Lilly USA, LLCMounjaro, Trulicity | $35 | $287,459242 claims |
| Boehringer IngelheimJardiance | $517 | $141,925146 claims |
| NovartisEntresto | $727 | $109,10697 claims |
| AstraZenecaFarxiga, Brilinta | $477 | $97,089116 claims |
| Sanofi-aventis U.S. LLCMultaq | $67 | $38,02530 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $177 | $13,52221 claims |
| Esperion Therapeutics, Inc.Nexlizet | $170 | $10,58924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Stavros StavrakisOklahoma City$174K
- Mark AndersonOklahoma City$113K
- Dwight ReynoldsOklahoma City$95K
- Udho ThadaniOklahoma City$91K
- Aly El BanayosyOklahoma City$54K
- Robert SullivanOklahoma City$36K
- Christina MurrayOklahoma City$29K
- Reji PappyOklahoma City$25K
- Gregory VanzantOklahoma City$23K
- Christine DiennaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.